| Code | Description | Claims | Beneficiaries | Total Paid |
| 99284 |
|
4,116 |
3,932 |
$3.02M |
| 99283 |
|
9,011 |
8,700 |
$2.12M |
| 87426 |
|
3,386 |
3,306 |
$160K |
| 87804 |
|
5,141 |
2,608 |
$139K |
| 99282 |
|
509 |
492 |
$88K |
| 80053 |
|
5,919 |
5,418 |
$81K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
3,239 |
3,142 |
$77K |
| 99285 |
|
296 |
273 |
$73K |
| 85025 |
|
6,119 |
5,608 |
$59K |
| 87880 |
|
641 |
619 |
$16K |
| 80307 |
|
175 |
172 |
$16K |
| 71045 |
|
521 |
472 |
$14K |
| 81001 |
|
2,500 |
2,376 |
$11K |
| 93005 |
|
679 |
605 |
$11K |
| 96374 |
|
386 |
374 |
$10K |
| 87420 |
|
243 |
238 |
$6K |
| 83690 |
|
621 |
598 |
$6K |
| 87070 |
|
426 |
412 |
$6K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
342 |
314 |
$2K |
| 84703 |
|
148 |
140 |
$2K |
| 96375 |
|
185 |
167 |
$2K |
| 76815 |
|
13 |
13 |
$1K |
| 81025 |
|
65 |
64 |
$861.61 |
| 84484 |
|
493 |
337 |
$746.04 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
233 |
214 |
$743.64 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
124 |
114 |
$731.86 |
| 96372 |
|
455 |
437 |
$665.71 |
| 36415 |
|
7,153 |
6,269 |
$604.68 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
395 |
330 |
$594.57 |
| 70450 |
|
33 |
31 |
$581.81 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
91 |
66 |
$473.75 |
| 83880 |
|
80 |
70 |
$431.05 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
263 |
225 |
$295.06 |
| 81003 |
|
53 |
52 |
$149.90 |
| 86328 |
|
21 |
21 |
$139.74 |
| 85610 |
|
58 |
51 |
$49.05 |
| 83735 |
|
47 |
41 |
$45.08 |
| 85730 |
|
28 |
25 |
$42.48 |
| 87086 |
|
27 |
27 |
$11.05 |
| A9270 |
Non-covered item or service |
336 |
283 |
$0.00 |
| 96361 |
|
13 |
13 |
$0.00 |
| 82962 |
|
31 |
16 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
12 |
12 |
$0.00 |